VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Unmet medical need in acute pain; H.R.1227/S.475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HANNAH BETH CORNWELL | — |
| ERIN MENDELSOHN | — |
| KRISTIN RICHTER | — |
| MATTHEW O SCHUMAKER | — |
| SWARNA VALLURUPALLI | — |
Taxation/Internal Revenue Code TAX
Issues related to corporate tax reform.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SWARNA VALLURUPALLI | — |
Budget/Appropriations BUD
Education about non-opioid pain therapies and patient access to non-opioid medicines, education on alternative funding programs, education on the Million Veteran Program at the VA.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HANNAH BETH CORNWELL | — |
| ERIN MENDELSOHN | — |
| KRISTIN RICHTER | — |
| MATTHEW O SCHUMAKER | — |
| SWARNA VALLURUPALLI | — |
Health Issues HCR
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (S.864); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HANNAH BETH CORNWELL | — |
| ERIN MENDELSOHN | — |
| KRISTIN RICHTER | — |
| MATTHEW O SCHUMAKER | — |
| SWARNA VALLURUPALLI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.